marijuana stock news

22nd Century Group to Host Webcast of 2020 Second Quarter Results

During the webcast, James A. Mish, Chief Executive Officer; Michael Zercher, Chief Operating Officer; and John Franzino, Chief Financial Officer, will review 2020 second quarter results.

Investors, analysts and members of the media interested in submitting questions in advance can do so by sending an e-mail to investorrelations@xxiicentury.com.

An archived replay of the webcast will also be available shortly after the live event has concluded.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Contacts:
Mei Kuo
22nd Century Group
(716) 300-1221
mkuo@xxiicentury.com

John Mills
ICR
(646) 277-1254
john.mills@icrinc.com

Deirdre Thomson
ICR
(646) 277-1283
deirdre.thomson@icrinc.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

HEXO Corp (HEXO) launches new Tsunami 30 g flower format exclusively to medical clients

HEXO launches new Tsunami 30 g flower format exclusively to medical clients…

GW Pharmaceuticals plc (GWPH) Receives Orphan Drug Designation from the European Medicines Agency

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)…

$CBIS Products in California Dispensaries

Cannabis Science Research Foundation Releases Preliminary CBIS Products in California Dispensaries Beginning…

InMed Pharmaceuticals Inc. (IMLFF) to Present at the 31st Annual ROTH Conference on March 19, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March…